ADVFN Logo ADVFN

Wir konnten keine Ergebnisse für:
Stelle sicher, dass deine Schreibweise korrekt ist oder versuche deine Suche zu erweitern.

Trends

Toplisten

Es scheint, dass du nicht eingeloggt bist.
Klicke auf den Button unten, um dich einzuloggen und deine zuletzt angesehenen Aktien zu sehen.

Registrieren

Bereits Mitglied? Einloggen

Pepperstone

Jetzt Handeln

Pepperstone
Marktdaten
News
Werkzeuge
Märkte
Entdecken

Hot Features

Follow Feed

Vernetzen Sie sich mit Händlern und Investoren in unserer Follow-Feed-Community.

Optionen-Flow

Erkunden Sie umfassende Optionsdaten und nutzen Sie erweiterte Filter mit Options Flow.

Watchlist

Organisieren und überwachen Sie Ihre Aktien- und Vermögensbeobachtungsliste mit dem Monitor.
Anmelden Premium IconPremium Help Menu
DAX
18.704,42
-0,11%
S&P 500
5.303,27
0,12%
Dow Jones
40.003,59
0,34%
Euro vs US Dollar
1,08945
-0,01%
Bitcoin
66.829,18
-0,38%
Registration Strip Icon for default Registrieren Sie sich kostenlos, um Echtzeitkurse, interaktive Charts, Live-Optionsfluss und mehr zu erhalten.
Registrieren
  1. Startseite
  2. Investieren
  3. Aktien
  4. USA
  5. NASDAQ
  6. Alkermes PLC (ALKS)

  7. Alkermes PLC (ALKS) News

ALKS

Alkermes (ALKS)

Alkermes PLC
Von:
Sortieren nach:
 Showing the most relevant articles for your search:NASDAQ:ALKS
DatumZeitQuelleÜberschriftSymbolFirma
14/05/202422h30Edgar (US Regulatory)Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) materialNASDAQ:ALKSAlkermes PLC
14/05/202413h00PR Newswire (US)Alkermes Highlights Data Presentations Related to its Psychiatry Franchise at Spring 2024 Scientific ConferencesNASDAQ:ALKSAlkermes PLC
14/05/202413h00PR Newswire (US)Alkermes Highlights Data Presentations Related to its Psychiatry Franchise at Spring 2024 Scientific ConferencesNASDAQ:ALKSAlkermes PLC
02/05/202413h00PR Newswire (US)Alkermes plc Completes Sale of Athlone, Ireland Facility to Novo NordiskNASDAQ:ALKSAlkermes PLC
01/05/202413h00PR Newswire (US)Alkermes plc Reports First Quarter 2024 Financial ResultsNASDAQ:ALKSAlkermes PLC
24/04/202413h00PR Newswire (US)Alkermes Announces Initiation of Vibrance-1 Phase 2 Study Evaluating ALKS 2680 for the Treatment of Narcolepsy Type 1NASDAQ:ALKSAlkermes PLC
17/04/202422h00PR Newswire (US)Alkermes to Report First Quarter Financial Results on May 1, 2024NASDAQ:ALKSAlkermes PLC
17/04/202422h00PR Newswire (US)Alkermes to Report First Quarter Financial Results on May 1, 2024NASDAQ:ALKSAlkermes PLC
09/04/202413h00PR Newswire (US)Alkermes Announces Positive Topline Results From Phase 1b Study of ALKS 2680 Demonstrating Improved Wakefulness in Patients With Narcolepsy Type 2 and Idiopathic HypersomniaNASDAQ:ALKSAlkermes PLC
09/04/202413h00PR Newswire (US)Alkermes Announces Positive Topline Results From Phase 1b Study of ALKS 2680 Demonstrating Improved Wakefulness in Patients With Narcolepsy Type 2 and Idiopathic HypersomniaNASDAQ:ALKSAlkermes PLC
08/04/202413h00PR Newswire (US)Alkermes Presents Analyses From Long-Term Safety Study of LYBALVI® (olanzapine and samidorphan) at 2024 Congress of the Schizophrenia International Research SocietyNASDAQ:ALKSAlkermes PLC
07/03/202413h09Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:ALKSAlkermes PLC
07/03/202413h00PR Newswire (US)Alkermes Announces Appointment of Nancy S. Lurker to Board of DirectorsNASDAQ:ALKSAlkermes PLC
27/02/202422h09Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:ALKSAlkermes PLC
27/02/202422h08Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:ALKSAlkermes PLC
27/02/202422h07Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:ALKSAlkermes PLC
27/02/202422h04Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:ALKSAlkermes PLC
27/02/202422h03Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:ALKSAlkermes PLC
23/02/202422h14Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:ALKSAlkermes PLC
23/02/202422h13Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:ALKSAlkermes PLC
23/02/202422h09Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:ALKSAlkermes PLC
23/02/202422h07Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:ALKSAlkermes PLC
23/02/202422h05Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:ALKSAlkermes PLC
23/02/202422h04Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:ALKSAlkermes PLC
21/02/202423h40Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:ALKSAlkermes PLC
21/02/202423h38Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:ALKSAlkermes PLC
21/02/202423h33Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:ALKSAlkermes PLC
21/02/202423h32Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:ALKSAlkermes PLC
21/02/202423h30Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:ALKSAlkermes PLC
21/02/202423h27Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:ALKSAlkermes PLC
 Showing the most relevant articles for your search:NASDAQ:ALKS

Kürzlich von Ihnen besucht

LSE
EMIG
Ubsetf Emig Esg
BTHB
FLOKIKRW
FLOKI
USOTC
FINMF
Leonardo (PK)
BITMOT
961322
Ebrd Tf 5% Ge26 Inr
ASX
TLSJOB
AMEX
BWEB
Bitwise Web3 ETF
BIT
F17999
Vontobel Financial Produ...
COIN
1ONEUSD
Harmony ONE
LSE
EDEN
Eden Research
ASX
SIQ
Smartgroup
LSE
SXLB
Spdr $ Material
EU
BE0002454297
TMVW TMVW4.7%11DEC28
NASDAQ
WFCABX
Wilmington Trust Fidelit...
NASDAQ
HBCP
Home Bancorp
GDAX
STGUSD
StargateToken
LSE
0IM3
Philly Shipyard Asa
Delayed Upgrade Clock
ADVFN Logo

Deutschland
Unternehmen
Geschäft
Popular
App herunterladen

Support: +44 (0) 203 8794 460 | support@advfn.de

Durch das Benutzen des ADVFN Angebotes akzeptieren Sie folgende Allgemeine Geschäftsbedingungen

© 2024 ADVFN PLC - Alle Rechte vorbehalten